In addition, Zhang et al. [39] indicated that frequent overexpression of CDK1 in human CRCs is associated with the therapeutic target, and the therapeutic resistance of BRAF mutant human CRC can be suppressed by targeting CDK1. Here, BRAF is linked to colorectal carcinoma.